98%
921
2 minutes
20
Tau is an intrinsically disordered protein implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. Here we describe the application of single-molecule Förster resonance energy transfer (smFRET) for the characterization of the interactions between tau and polyphosphate, an intracellular polymer that accelerates tau aggregation. We describe the design of tau constructs, purification and fluorescent labeling of tau, and details of acquisition and analysis of smFRET data. The protocols provided here outline an approach that may be applied to the study of other intrinsically disordered proteins and their binding partners.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386101 | PMC |
http://dx.doi.org/10.1007/978-1-0716-0524-0_39 | DOI Listing |
Redox Biol
September 2025
Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. Electronic address:
Anti-IgLON5 disease is an autoimmune encephalitis with more chronic presentation including memory decline, sleep disorder, bulbar symptoms and movement disorder. Post-mortem brains of patients with anti-IgLON5 disease show neurodegeneration with tau deposition sparking interest in this 'acquired tauopathy' as a disease model for neurodegeneration, yet mechanisms of neurodegeneration remain unknown. Using a reductionist human iPSC-derived neuron-antibody model, we applied proteomics approach, electrophysiology and live cell imaging.
View Article and Find Full Text PDFAlzheimers Dement (Amst)
September 2025
Introduction: Simple screening tools are critical for assessing Alzheimer's disease (AD)-related pre-dementia changes. This study investigated longitudinal scores from the Quick Dementia Rating System (QDRS), a brief study partner-reported measure, in relation to baseline levels of the AD biomarker plasma pTau217 in individuals unimpaired at baseline.
Methods: Data from the Wisconsin Registry for Alzheimer's Prevention (N = 639) were used to examine whether baseline plasma pTau217 (ALZpath assay on Quanterix platform) modified QDRS or Preclinical Alzheimer's Cognitive Composite (PACC3) trajectories (mixed-effects models; time = age).
Neurology
October 2025
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain.
Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
View Article and Find Full Text PDFACS Omega
September 2025
Instituto de Macromoléculas Professora Eloisa Mano, Universidade Federal do Rio de Janeiro (IMA/UFRJ), Rio de Janeiro, Rio de Janeiro 21941-598, Brazil.
This study reports the synthesis and functionalization of poly-(-vinylcarbazole) (PVK) with anthracene units to enhance its blue photoluminescence properties. Structural and thermal analyses confirmed successful incorporation of anthracene moieties into the PVK backbone at an approximate 3:1 ratio of PVK repeat unit to anthracene. Photophysical characterization showed that anthracene-functionalized PVK (PVK-An) retained blue-region emission (432 nm), although with reduced emission efficiency due to π-π stacking interactions.
View Article and Find Full Text PDFAm J Med
September 2025
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; School of Medicine, Stanford University, Stanford, CA, USA. Electronic address:
Background: Recurrent hospitalizations present significant financial burdens and health risks. Poor communication and lack of personalized care are major contributors to preventable readmissions. This study examined whether brief, personal conversations between physicians and hospitalized -patients could reduce 1-week and 30-days post-discharge readmissions, and improve satisfaction.
View Article and Find Full Text PDF